Latest other current liabilities for NKTR: $23M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Nektar Therapeutics (NKTR) currently reports a other current liabilities of $23M as of June 2026. That compares with $35M in the prior-year period — down 33.4% year over year. Use the charts on this page to explore Nektar Therapeutics's other current liabilities history and peer comparisons.
Nektar Therapeutics's other current liabilities decreased from $35M to $23M — a 33.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Nektar Therapeutics reported $23M in other current liabilities as of June 2026. That compares with $35M in the prior-year period — down 33.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current other current liabilities of $23M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Nektar Therapeutics, and consider following NKTR for alerts when major investors trade the stock.
Nektar Therapeutics is classified in the Healthcare sector. On other current liabilities, it currently shows $23M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NKTR with unrelated industries.